CA2500715A1 - Hla binding peptides and their uses - Google Patents

Hla binding peptides and their uses Download PDF

Info

Publication number
CA2500715A1
CA2500715A1 CA002500715A CA2500715A CA2500715A1 CA 2500715 A1 CA2500715 A1 CA 2500715A1 CA 002500715 A CA002500715 A CA 002500715A CA 2500715 A CA2500715 A CA 2500715A CA 2500715 A1 CA2500715 A1 CA 2500715A1
Authority
CA
Canada
Prior art keywords
human
hpv
hiv
sequence
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002500715A
Other languages
English (en)
French (fr)
Inventor
John Sidney
Scott Southwood
Alessandro Sette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Epimmune Inc
IDM Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc, IDM Pharma Inc filed Critical Epimmune Inc
Publication of CA2500715A1 publication Critical patent/CA2500715A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002500715A 2002-10-03 2003-10-03 Hla binding peptides and their uses Abandoned CA2500715A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41620702P 2002-10-03 2002-10-03
US60/416,207 2002-10-03
US41726902P 2002-10-08 2002-10-08
US60/417,269 2002-10-08
PCT/US2003/031308 WO2004031211A2 (en) 2002-10-03 2003-10-03 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
CA2500715A1 true CA2500715A1 (en) 2004-04-15

Family

ID=32073406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002500715A Abandoned CA2500715A1 (en) 2002-10-03 2003-10-03 Hla binding peptides and their uses

Country Status (6)

Country Link
US (1) US20060079453A1 (https=)
EP (1) EP1578432A4 (https=)
JP (1) JP2006512300A (https=)
AU (1) AU2003291632A1 (https=)
CA (1) CA2500715A1 (https=)
WO (1) WO2004031211A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433667B2 (en) 2006-09-28 2016-09-06 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US12076381B2 (en) 2015-08-05 2024-09-03 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
WO2004053086A2 (en) * 2002-12-06 2004-06-24 Epimmune, Inc. Plasmodium falciparum antigens and methods of use
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
PT2236608T (pt) 2005-10-04 2017-03-01 Soligenix Inc Péptidos novos para tratar e prevenir distúrbios relacionados com a imunidade, incluindo tratar e prevenir infecção por modulação da imunidade inata
ES2616341T3 (es) * 2006-03-10 2017-06-12 Peptcell Limited Péptidos de proteínas reguladoras o accesorias de VIH, composiciones y la utilización de las mismas
US8361479B2 (en) 2006-08-11 2013-01-29 Dendreon Corporation Promiscuous PAP CD4 T cell epitopes
WO2008086813A2 (en) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides derived from proteins of the insulin super-family
CN101688205B (zh) * 2007-05-16 2013-07-24 基因信号国际公司 抗肿瘤药物、药剂、组合物及其用途
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009046739A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
KR20090125629A (ko) * 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
FR2940125B1 (fr) 2008-12-23 2013-03-22 Isp Investments Inc Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase
FR2940291B1 (fr) 2008-12-23 2012-12-21 Isp Investments Inc Peptide derive d'hmg-coa reductase et composition cosmetique ou pharmaceutique le contenant
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
FR2944526B1 (fr) 2009-04-15 2013-05-10 Isp Investments Inc Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barriere
FR2944445B1 (fr) 2009-04-15 2013-08-16 Isp Investments Inc Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique apaisant
US8933036B2 (en) 2009-04-15 2015-01-13 Isp Investments Inc. Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
WO2011127099A1 (en) 2010-04-05 2011-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2012046238A2 (en) * 2010-10-06 2012-04-12 Ramot At Tel-Aviv University Ltd. Erythropoietin receptor antagonists
EP2694709B1 (en) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
JP2011239787A (ja) * 2011-08-15 2011-12-01 Igaku Seibutsugaku Kenkyusho:Kk エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
EP4592400A3 (en) 2012-10-17 2025-10-29 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
EP3736573A1 (en) 2013-03-15 2020-11-11 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
CA2916662C (en) 2013-06-25 2022-03-08 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
EP3901282B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065623A2 (en) * 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
KR20190129032A (ko) 2016-12-28 2019-11-19 인벡스, 인크. 인플루엔자 백신
EP3545967A1 (en) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer immunization platform
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
AU2019331903A1 (en) * 2018-08-31 2021-03-11 3T Biosciences, Inc. Randomized peptide libraries presented by human leukocyte antigens
CN110240644B (zh) * 2019-06-28 2021-03-16 深圳市亚辉龙生物科技股份有限公司 人生长激素受体突变体、人生长激素免疫原、多克隆抗体及检测试剂盒
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN111704651B (zh) * 2020-07-27 2021-10-08 南京安吉生物科技有限公司 具有抗衰老作用的多肽rv3和rv4及其应用
CN112898401A (zh) * 2021-02-05 2021-06-04 合肥瑞城生生物科技有限公司 一种钙网蛋白组合肽及其用途
JP2026507123A (ja) 2023-02-28 2026-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性化剤およびその使用方法
CN120346307A (zh) * 2025-04-09 2025-07-22 新抗原医学科技(杭州)有限公司 一种靶向纳米脂质体的新型肿瘤疫苗的制备方法及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4434264A (en) * 1983-03-22 1984-02-28 El Paso Polyolefins Company High clarity propylene polymer compositions of improved impact strength
US4532280A (en) * 1984-06-11 1985-07-30 New Japan Chemical Co., Ltd. Crystalline polyolefin-type resin compositions
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5753233A (en) * 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6015854A (en) * 1997-10-24 2000-01-18 Union Carbide Chemicals & Plastics Technology Corporation Polypropylene impact copolymers with high clarity
EP1242108B1 (en) * 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040037840A1 (en) * 2000-10-27 2004-02-26 Beier Anne Mette Novel therapeutic vaccine formulations
US6599964B2 (en) * 2001-03-23 2003-07-29 Milliken & Company Symmetric substituted benzaldehyde alditol derivatives and compositions and articles containing same
US6562890B2 (en) * 2001-03-29 2003-05-13 Milliken & Company Disodium hexahydrophthalate salt compositions and nucleated polymers comprising such compositions

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433667B2 (en) 2006-09-28 2016-09-06 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US10226519B2 (en) 2006-09-28 2019-03-12 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US11096996B2 (en) 2013-02-14 2021-08-24 Precision Lifesciences Group Llc Cancer vaccines and vaccination methods
US12076381B2 (en) 2015-08-05 2024-09-03 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US12097249B2 (en) 2015-08-05 2024-09-24 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US12102670B2 (en) 2015-08-05 2024-10-01 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US12144852B2 (en) 2015-08-05 2024-11-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US12180259B2 (en) 2015-08-05 2024-12-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Also Published As

Publication number Publication date
WO2004031211A2 (en) 2004-04-15
AU2003291632A1 (en) 2004-04-23
JP2006512300A (ja) 2006-04-13
EP1578432A2 (en) 2005-09-28
EP1578432A4 (en) 2008-07-30
US20060079453A1 (en) 2006-04-13
AU2003291632A2 (en) 2004-04-23
WO2004031211A8 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
CA2500715A1 (en) Hla binding peptides and their uses
US7252829B1 (en) HLA binding peptides and their uses
US9340577B2 (en) HLA binding motifs and peptides and their uses
EP1911461B1 (en) HLA class I and II binding peptides and their uses
EP1917970B1 (en) Hla binding peptides and their uses
AU725550B2 (en) HLA binding peptides and their uses
US6689363B1 (en) Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
CA2248667C (en) Hla-a2.1 binding peptides and their uses
US20020098197A1 (en) Hla binding peptides and their uses
US20030152580A1 (en) Hla binding peptides and their uses
WO2001062776A1 (en) Hla binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
EP1089757B1 (en) Hla binding peptides and their uses
EP1343819A1 (en) Hla-a2.1 binding peptides and their uses
CA2421445A1 (en) Hla binding peptides and their uses
EP1313505A1 (en) Hla binding peptides and their uses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued